FCGR3A and neuroblastoma: For high-risk neuroblastoma, immunotherapy with GD2-specific monoclonal antibodies that can trigger antibody-dependent cell-mediated cytotoxicity (ADCC) of NK cells via activation of FcγRIIIa (CD16) has markedly increased survival rates [42].